Cardiovascular effects of prenalterol (H133/22) in normal man

British Journal of Clinical Pharmacology
D H ScottD B Scott


1 Prenalterol, (S-(-)-1-(4 hydroxyphenoxy)-3-isopropylaminopropanol-2 hydrochloride) a cardio-selective beta-adrenergic receptor agonist, was infused intravenously into six normal male volunteers to determine the cardiovascular effects of this drug. 2 On different occasions, each volunteer received a placebo infusion, an infusion of 0.5 mg prenalterol and an infusion of 1 mg prenalterol. Cardiac output (impedance cardiography), arterial pressure (sphygmomanometry), heart rate and ECG were measured throughout. 3 Prenalterol produced a statistically significant increase in cardiac output and at the end of the infusion this increase was 24% with 0.5 mg and 29% with 1 mg, mainly due to an increase in stroke volume (18% and 17%) with a lesser change in heart rate (+2 and +7 beats/min). Pulse pressure increased but mean arterial pressure showed little change. Peripheral resistance fell by 18% and 20%. As indicated by systolic time indices myocardial contractility increased. 4 Prenalterol at plasma concentrations in excess of 20 nmol l-1 produced significant inotropic effects but did not markedly increase heart rate at concentrations of 60 nmol l-1.


Jan 1, 1985·European Journal of Clinical Pharmacology·E J SainsburyJ J Ashley
Jan 1, 1984·European Journal of Clinical Pharmacology·J Ladefoged
Oct 1, 1980·European Journal of Clinical Pharmacology·T L SvendsenJ Trap-Jensen
Jan 1, 1981·European Journal of Clinical Pharmacology·C GraffnerO Rönn
Nov 1, 1980·European Journal of Clinical Pharmacology·A WeissU C Dubach
Jan 1, 1982·Pharmacology & Therapeutics·D B EvansH R Kaplan
May 1, 1983·Clinical and Experimental Pharmacology & Physiology·A BranziB Magnani
Jan 1, 1985·Acta Physiologica Scandinavica·J A AskF Resch
Jun 1, 1987·Acta Physiologica Scandinavica·B Wohlfart, A R Khan
Jan 1, 1983·European Journal of Clinical Pharmacology·A P Greefhorst, C L van Herwaarden
Apr 15, 1980·Klinische Wochenschrift·K A MeurerA Helber
May 1, 1984·Anaesthesia·D OstergaardT Pedersen
Jun 1, 1982·Journal of Clinical and Hospital Pharmacy·M J KendallS Westerling
Oct 1, 1980·Anaesthesia·D H ScottD B Scott
Aug 1, 1985·Acta Anaesthesiologica Scandinavica·J StrømM Bredgaard Sørensen
Oct 1, 1982·Acta Anaesthesiologica Scandinavica·H TydénS O Nyström
Dec 1, 1982·Acta Anaesthesiologica Scandinavica·P O Järnberg, L Westman
Apr 1, 1988·Journal of Endocrinological Investigation·C TantucciV Grassi
Jan 1, 1982·Acta Anaesthesiologica Scandinavica. Supplementum·K E Andersson
Jan 1, 1982·Acta Medica Scandinavica. Supplementum·E N MooreG Adler
Jan 1, 1981·Acta Medica Scandinavica. Supplementum·K E Andersson
Apr 1, 1988·Scandinavian Journal of Clinical and Laboratory Investigation·S R Johansson, A Hjalmarson
Jan 1, 1982·Acta Medica Scandinavica. Supplementum·W DoeringJ Isbary
Jan 1, 1982·Acta Medica Scandinavica. Supplementum·L EkB Johansson
Jan 1, 1982·Acta Medica Scandinavica. Supplementum·T AnderssonH Mattsson
Jan 1, 1982·Acta Medica Scandinavica. Supplementum·H A Wester, D Oltmanns
Dec 1, 1982·Naunyn-Schmiedeberg's Archives of Pharmacology·H MattssonT Olsson


Nov 10, 1977·Naunyn-Schmiedeberg's Archives of Pharmacology·E CarlssonB Tångstrand
May 31, 1978·European Journal of Clinical Pharmacology·G JohnssonJ Wikstrand
Dec 1, 1977·Intensive Care Medicine·L I Goldberg
Jan 1, 1976·Acta Anaesthesiologica Scandinavica·D W Hill, A J Merrifield

Related Concepts

Arterial Pulse Pressure
Total Peripheral Resistance
Myocardial Disorder
Human Volunteers
Diastolic Blood Pressure
Adrenergic beta-Agonists
Pulmonary Vascular Resistance

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Synapse Loss as Therapeutic Target in MS

As we age, the number of synapses present in the human brain starts to decline, but in neurodegenerative diseases this occurs at an accelerated rate. In MS, it has been shown that there is a reduction in synaptic density, which presents a potential target for treatment. Here is the latest research on synapse loss as a therapeutic target in MS.

Artificial Intelligence in Cardiac Imaging

Artificial intelligence (ai) techniques are increasingly applied to cardiovascular (cv) medicine in cardiac imaging analysis. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

Social Learning

Social learning involves learning new behaviors through observation, imitation and modeling. Follow this feed to stay up to date on the latest research.

Cell Atlas of the Human Eye

Constructing a cell atlas of the human eye will require transcriptomic and histologic analysis over the lifespan. This understanding will aid in the study of development and disease. Find the latest research pertaining to the Cell Atlas of the Human Eye here.

Single Cell Chromatin Profiling

Techniques like ATAC-seq and CUT&Tag have the potential to allow single cell profiling of chromatin accessibility, histones, and TFs. This will provide novel insight into cellular heterogeneity and cell states. Discover the latest research on single cell chromatin profiling here.

Genetic Screens in iPSC-derived Brain Cells

Genetic screening is a critical tool that can be employed to define and understand gene function and interaction. This feed focuses on genetic screens conducted using induced pluripotent stem cell (iPSC)-derived brain cells.